Due to the small samples size of the analyzed cohort, the results were not statistically significant; however, patients with both T0 and T1 EGFR mutations showed a trend for worse progression-free survival compared to patients without EGFR mutations detected on ctDNA ( p = 0.14, Log-Rank Test).
Left STR and left SFG also showed a trend toward sensitivity to Factor 1 [1-tailed t (15) = 1.13, p = 0.14 and 1-tailed t (15) = 1.16, p = 0.13, respectively].
The group with stage IB1 tumors >2 cm had statistically deeper cervical stromal invasion (9.99±5.04 mm, p<0.001, Kruskal-Wallis test), higher incidences of LVSI (45.3%, p = 0.002, chi-square test), and greater lymph node metastasis (24.2%, p = 0.002, chi-square test) compared to the other 2 groups (stage IA2 and stage IB tumors ≤2 cm).The group with stage IB1 tumors >2 cm showed a trend toward a higher incidence of parametrial invasion (9.5%, p = 0.14, chi-square test) compared with the other two groups (stage IA2 tumor, 0%;stage IB1 tumor ≤2 cm, 4%), though it did not reach statistical significance.
Of interest, after 24 h the four individuals with highest LLS showed a trend towards lower IL-10 plasma concentrations (lowest LLS 4.02 (2.18–7.13) pg/mL vs. highest LLS 1.80 (0.91–2.48) pg/mL, p = 0.14). 2.5.2.
Outcome analysis in the whole cohort (Table 2 ) showed a trend towards a reduction of stage 2–3 AKI in the HOPE group (87 [32.3%] versus 4 [16%]; p = 0.140).
No such increase was found for IFN-γ, which showed a trend towards decreased production in skin-homing cells (0.7 mean fold increase, P = 0.14).
Only the model built on CDT score showed a trend to significance (F (22, 31) = 1,52; p = 0.14), suggesting that CDT score could be positively associated with the APOEε3 allele (2,2; 95% CI [0,03 0,8]; p = 0.037).
Chi-square tests of independence showed that the success rate was not dependent on the age or gender, but the patients showed a trend of lower success rate (p = 0.14) compared to healthy controls.
In regions with low VEGFR2 expression, this difference was not significant but again showed a trend toward higher expression in HPV-negative tumors ( Figure 3 A; p = 0.140).
20 showed a trend to a longer fluoroscopy time when using the novel ablation system (14.0 vs. 10.8 min; P = 0.141).
Indeed, RT-PCR analyses of the mRNA of cultured embryos at E9 that had been exposed to glucose for only 7 h showed a trend, albeit not one that was significant ( Daam1 expression P =0.142; Vangl2 expression P =0.086), towards weaker Daam1 and Vangl2 expression.
Higher comorbidity burden showed a trend toward longer hospital stay but was not associated with mortality (aOR = 2.9, 95% CI: 0.70–11.76, p = 0.142; IPW logit with an ATE = +0.016, 95% CI: −0.03–0.06, p = 0.482).
When these cases are excluded from survival analyses, median survival was not significantly different, but still showed a trend in favor of the non-AC group, with a median survival of 105 months for AC patients and 136 months for non-AC patients ( p = 0.142).
AD Resilient rats also showed a trend toward fewer inhibitory neurons diverging to two to five inhibitory targets compared with AD Impaired rats ( p = 0.142; Figure 7J ).
CEUS to absolute dose applied (per cycle 1; Supplementary Tables S2 and S4 ) showed a trend (correlation coefficient r = 0.498, p = 0.142), and DCE-MRI VVF measurements showed a significant correlation with absolute dose applied per cycle 1 (r = 0.556, p = 0.038) but not with dose level per m 2 , whereas k-trans measurements only showed trends.
This showed a trend toward CST IV/V in mid/late menopause compared to early (65.9% vs. 41.2%, p =0.142).
The overall rate of death showed a trend of reduction of 36% (RR [CI] = 0.64 [0.35, 1.16], p = 0.143) in the MSC treatment group.
While the age group distribution showed a trend toward higher medical use among the 65+ cohort (62.3%), this did not reach statistical significance in the bivariate analysis ( p = 0.143).
Furthermore, subgroup analysis showed a trend towards a benefit of D2 dissection in patients with locally advanced gastric cancer > T1 (DSS 55% for D1 vs. 69% for D2 with p = 0.143) and in N + patients (OS rate of 35% for D1 vs. 51% for D2 and DSS rate of 38% for D1 vs. 59% for D2) and in patients with T2-T4 and N+.
Similarly, the incidence of SFSS in the current policy group also showed a trend toward being lower than in the previous policy group (25.0% vs 55.2%, P =0.143).
Patients with any positive autoimmune antibody (anti-SOX2, anti-Hu, anti-Yo, anti-VGCCA, anti-VGPCA, anti-nuclear, anti-neutrophil cytoplasmic antibodies) showed a trend for a prolonged survival (18.5 versus 17 months, p = 0.144), a significantly longer median progression free survival (8.8 versus 7.3 months, p = 0.036) and a trend for a higher response rate ( p = 0.066) [ 85 ].
The Cox proportional hazard regression analyses showed a trend of survival benefit of MetS after adjustment of age, diabetes mellitus, serum levels of total cholesterol, and triglyceride (HR: 0.71, 95% CI: 0.45-1.12, P=0.144) ( Figure 1 ).
Occupations showed a trend towards association (p=0.144), indicating that individuals engaged in fishing and farming faced a higher risk of schistosomiasis (OR 3.233 [95% CI 0.602to 16.867]).
Comparing the VF-14 scores of late onset-LHON patients with symptomatic carriers with onset <50 years showed a trend to lower scores for the older patients (18.06+/−15.27 versus 25.14+/−21.18, p = 0.144).
1.0 ± 0.2, p = 0.046), and SDHA expression showed a trend for higher expression (2.5 ± 0.6 vs. 1.6 ± 0.3, p = 0.144). 3.6.